Full Text
Cost-Effectiveness of Ceritinib In Previously Untreated ALK-Positive Non-Small Cell Lung Cancer in the United Kingdom

Abstract

Authors

J Xie S Knoll A Slowley A Bensimon J Vieira J Chilcott S Paisley Z Zhou

Back to Volume 21, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×